Close menu




Comments

Photo credits: pixabay.com

Commented by Fabian Lorenz on January 17th, 2024 | 07:00 CET

Disaster at Plug Power! Opportunities with Thyssenkrupp Nucera and First Hydrogen shares!

  • Hydrogen
  • greenhydrogen
  • renewableenergies

The share price horror at hydrogen pioneers Nel and Plug Power continues in the new year. Yesterday alone, Plug Power's share price fell by more than 6% and has lost almost 30% of its value in just a few days of trading. Nel does not fare much better. Does this mean the comeback of hydrogen shares will fail in 2024? Investors should take a closer look at Plug Power; after all, the management itself has announced that it could run out of money. In terms of valuation and operational development, the two newcomers, First Hydrogen and Thyssekrupp Nucera, appear to be more attractive than the top dogs. Experts believe that First Hydrogen's shares, with their current market capitalization of CAD 80 million and further solid development in 2023, are currently on a special offer. And with Thyssenkrupp Nucera, analysts see around 90% upside potential.

Read

Commented by Armin Schulz on January 16th, 2024 | 07:30 CET

Commerzbank, Globex Mining, Vonovia - Interest Rates, Commodities, Real Estate - Where is the most potential?

  • Mining
  • Gold
  • Commodities
  • RealEstate
  • Banking

When it comes to investing one's money, investors have various options. Personal preferences and different risk tolerances play a crucial role in decision-making. Should one choose the security of a bank with fixed interest rate products, or does one venture into the potentially lucrative terrain of the commodities markets, where choices range between gold, oil and many other options? The third option would be real estate, the ownership of which is equated with value stability and protection against inflation. Experts recommend a diversified approach across these different areas to cushion fluctuations. We take a look at an interesting company from each sector.

Read

Commented by André Will-Laudien on January 16th, 2024 | 07:15 CET

E-mobility boom 2024, when will the German vehicle market take off? BYD, Edison Lithium, VW, BMW

  • Mining
  • Lithium
  • Batteries
  • renewableenergies
  • Electromobility

The last word in e-mobility has not yet been spoken. While BYD is leading the sales list worldwide, Tesla is struggling with important supplier parts and has had to halt production temporarily. German manufacturers have used the last two years to catch up on technical backlogs and are preparing to score points in the "electric world", too. Last year, buyers were offered a state environmental bonus on top, but this was cancelled before Christmas. Now, the market has to prove that it can survive with fewer subsidies. Where are the opportunities for investors?

Read

Commented by Stefan Feulner on January 16th, 2024 | 07:00 CET

Nel Asa, Altech Advanced Materials, Nordex - Now the analysts speak

  • Technology
  • Innovations
  • renewableenergies

Here we go again; the eagerly awaited reporting season began last week. After the major banks initially published their figures, both positive and negative surprises are likely to dominate the markets until mid-February. Several analyst firms have already expressed their forecasts and adjusted their share price targets in advance. The performance of companies in the renewable energy sector is likely to be particularly exciting. High volatility is guaranteed here.

Read

Commented by André Will-Laudien on January 15th, 2024 | 06:45 CET

Biotech: Corona is back! The doublers are lurking here: BioNTech, Evotec, Defence Therapeutics and Bayer

  • Biotechnology
  • Pharma
  • Covid19

We had almost forgotten about Corona and the good old flu, but it is back in full swing. Governments are remaining calm and holding on to their regained liberalism. However, Spain is now resorting to drastic measures again to protect vulnerable population groups. A mask is to be compulsory again in all Spanish healthcare facilities due to the increase in respiratory diseases. Health Minister Mónica García had previously failed to convince the Spanish regions of the need to introduce compulsory masks of their own accord. In some parts of the country, hospital emergency rooms are under severe pressure due to high patient numbers. Biotech stocks are showing the first signs of recovery after the sell-off in 2023. We take a look at a few selected stocks with 100% potential.

Read

Commented by Stefan Feulner on January 15th, 2024 | 06:30 CET

Hertz, Saturn Oil + Gas, Occidental Petroleum - Clear signs of a trend reversal

  • Mining
  • Oil
  • Electromobility

Electromobility, often hailed as the future of transportation, is at the forefront of a global transport revolution. A swansong has already been sung for the traditional combustion engine. However, the fossil fuel-powered vehicle is still by far the best-selling vehicle. Issues with battery-powered vehicles are increasing. In addition to the continuing lack of refueling infrastructure, the purchase prices are simply too high without government subsidies. Additionally, higher repair costs are becoming more prevalent.

Read

Commented by Armin Schulz on January 11th, 2024 | 07:30 CET

Altech Advanced Materials, BYD, JinkoSolar - The Era of Energy Autonomy

  • renewableenergies
  • Energy
  • Innovations
  • Technology

In an era where energy not only needs to be generated but also intelligently managed, batteries and energy storage systems are increasingly taking centre stage. They are the inconspicuous heroes of the energy transition that will significantly shape our understanding of sustainability. While renewable energy from sun, wind and water is increasingly feeding into our power grid, reliable storage solutions are the key to using energy where and when it is actually needed. We look at Altech Advanced Materials, a company offering two exciting solutions for the future, and examine BYD, the top dog of electromobility alongside Tesla. Lastly, we explain why JinkoSolar can benefit from future energy storage systems.

Read

Commented by Juliane Zielonka on January 11th, 2024 | 07:15 CET

From innovative cancer therapy to menopause: How Defence Therapeutics, Bayer and NVIDIA are reshaping the medical landscape

  • Biotechnology
  • Pharma

The global prevalence of lung cancer as the second most common cancer and the challenges associated with it have led Defence Therapeutics to develop an innovative solution. Through unconventional nasal delivery, following the motto "through the nose to the lungs", the non-hormonal drug enables the precise distribution of the active ingredient. This advance could replace conventional surgical procedures for lung cancer and open up new avenues in cancer therapy. Bayer aims to generate EUR 1 billion in sales in women's health. The drug aims to alleviate the many symptoms of menopause effectively and opens up new revenue prospects for Bayer in the field of women's health. NVIDIA brings pharmaceutical research into the digital age. BioNeMo, a generative AI platform, enables research and development teams to represent drugs directly on the computer. Discover the opportunities emerging for investors now.

Read

Commented by Fabian Lorenz on January 11th, 2024 | 07:00 CET

Evotec is in the analyst check, Tui with Wanderlust, and another 100% gain for Manuka Resources?

  • Mining
  • Vanadium
  • Gold
  • Silver
  • travel
  • Biotechnology

The Evotec stock is currently not for the faint-hearted. After the resignation of the long-serving board member caused uncertainty, the biotech company was able to reassure investors with a milestone payment. Analysts are speaking out and expressing their opinions, and a real "bull" is among them. And what about Manuka Resources? At the beginning of December, news about an exciting project for battery metals caused a jump in the share price. Is it now worth getting in after the consolidation? The Tui share has also recently consolidated after a 50% gain within a few weeks. Analysts' price targets for the tourism company's shares vary widely. Hold or buy?

Read

Commented by Juliane Zielonka on January 10th, 2024 | 12:00 CET

Cardiol Therapeutics, Morphosys, BioNTech - Who will switch to the fast lane in 2024?

  • Biotechnology
  • Cancer

The life science and biotech sector has a few aces up its sleeve in 2024. Cardiol Therapeutics announces a significant clinical milestone, with over 50% of participants now enrolled in the ARCHER trial for acute myocarditis. MorphoSys, a cancer drug company, is developing an oral therapy specifically for proteins against myelofibrosis with the promising compound "pelabresib". However, analysts disagree on the share valuation. Top dog BioNTech is planning sales of EUR 3 billion in 2024, also focusing on oncology. CEO Uğur Şahin emphasizes the strategic scaling of the cancer therapy business by 2025 and initial market launches by 2026. Who will use 2024 to move into the fast lane?

Read